| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FTI-277 | GDSC1000 | pan-cancer | AAC | 0.068 | 0.09 |
| mRNA | BRD-K24690302 | CTRPv2 | pan-cancer | AAC | -0.07 | 0.09 |
| mRNA | BRD-K30748066 | CTRPv2 | pan-cancer | AAC | -0.25 | 0.09 |
| mRNA | OSI-027 | GDSC1000 | pan-cancer | AAC | -0.061 | 0.09 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | -0.068 | 0.1 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | -0.095 | 0.1 |
| mRNA | 17-AAG | FIMM | pan-cancer | AAC | -0.37 | 0.1 |
| mRNA | BRD-K09344309 | CTRPv2 | pan-cancer | AAC | -0.15 | 0.1 |
| mRNA | neopeltolide | CTRPv2 | pan-cancer | AAC | -0.13 | 0.1 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.064 | 0.1 |